RENAL CELL CARCINOMA (RCC) THERAPY USING GENETICALLY ENGINEERED T CELLS TARGETING CD70

摘要

Aspects of the present disclosure relate to compositions comprising a population of genetically engineered T cells that expresses a chimeric antigen receptor (CAR) that binds CD70, and methods of using such for the treatment of renal cell cancer (RCC).